POPULATION PHARMACOKINETIC MODELS - EFFECT OF EXPLICIT VERSUS ASSUMED CONSTANT SERUM CONCENTRATION ASSAY ERROR PATTERNS UPON PARAMETER VALUES OF GENTAMICIN IN INFANTS ON AND OFF EXTRACORPOREAL MEMBRANE-OXYGENATION

被引:47
作者
DODGE, WF
JELLIFFE, RW
ZWISCHENBERGER, JB
BELLANGER, RA
HOKANSON, JA
SNODGRASS, WR
机构
[1] UNIV TEXAS, MED BRANCH, DEPT PHARMACOL & TOXICOL, GALVESTON, TX 77550 USA
[2] UNIV TEXAS, MED BRANCH, DEPT SURG CARDIOTHORAC SURG, GALVESTON, TX 77550 USA
[3] METHODIST HOSP, DEPT CLIN SERV PHARM, SAN ANTONIO, TX USA
[4] UNIV SO CALIF, SCH MED, DEPT MED, APPL PHARMACOKINET LAB, LOS ANGELES, CA USA
关键词
POPULATION MODELS; LABORATORY ERROR ASSAY PATTERN; GENTAMICIN; EXTRACORPOREAL MEMBRANE OXYGENATION; TERM INFANTS;
D O I
10.1097/00007691-199412000-00004
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 [基础医学];
摘要
Prior authors had hypothesized (but not clearly found) an increased apparent volume of distribution (V-d) for gentamicin in neonates undergoing extracorporeal membrane oxygenation (ECMO). We chose to study the question in our own clinical setting. To develop population pharmacokinetic models of the drug, we used the nonparametric expectation and maximization population modeling method and data from 11 neonates who received gentamicin on ECMO, including 6 infants who received gentamicin both on and off ECMO for severe respiratory failure. We found an increased V-d for gentamicin on ECMO and attributed much of the difference from prior investigations to our use of an explicitly determined laboratory assay error pattern for the measured serum concentrations rather than using constant weighting of the serum revel data points. For six infants, while on ECMO their median V-d was 0.748 L/kg compared with a median V-d of 0.471 L/kg after ECMO was discontinued. The median clearance of gentamicin in the six infants while undergoing ECMO was 0.239 L/h compared with 0.350 Lih after ECMO was discontinued. The median half-time (T-1/2) was 9.24 h while on ECMO compared with 3.87 h when off ECMO. We conclude that while undergoing ECMO, neonates have a higher volume of distribution for gentamicin, a lower clearance, and a much longer half-life. Based on these results, for attainment of the desired peak-and-trough plasma gentamicin concentrations for infants undergoing ECMO (i.e., 5-8 and <2.0 mu g/ml, respectively), we now recommend a loading dose of similar to 4.3 mg/kg of gentamicin and a maintenance dose of similar to 3.7 mg/kg to be given at dosing intervals of 18-24 h, followed by monitoring of serum concentrations and appropriate dose adjustments thereafter. To attain alternative goals, the model provides different loading and maintenance doses.
引用
收藏
页码:552 / 559
页数:8
相关论文
共 17 条
[1]
DESIGN OF DOSAGE REGIMENS - A MULTIPLE MODEL STOCHASTIC-CONTROL APPROACH [J].
BAYARD, DS ;
MILMAN, MH ;
SCHUMITZKY, A .
INTERNATIONAL JOURNAL OF BIO-MEDICAL COMPUTING, 1994, 36 (1-2) :103-115
[2]
BHATTMEHTA V, 1992, PHARMACOTHERAPY, V12, P28
[3]
EFFECT OF EXTRACORPOREAL MEMBRANE-OXYGENATION ON BODY-WATER CONTENT AND DISTRIBUTION OF BABOON NEONATES [J].
BRANS, YW ;
CORNISH, JD ;
KUEHL, TJ ;
DUTTON, EB ;
ANDREW, DS ;
MENCHACA, EM .
PEDIATRIC RESEARCH, 1986, 20 (05) :381-384
[4]
GENTAMICIN PHARMACOKINETICS IN NEONATES UNDERGOING EXTRACORPOREAL MEMBRANE-OXYGENATION [J].
COHEN, P ;
COLLART, L ;
PROBER, CG ;
FISCHER, AF ;
BLASCHKE, TF .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1990, 9 (08) :562-566
[5]
DEBORD J, IN PRESS INT J BIOME
[6]
POPULATION PHARMACOKINETIC MODELS - MEASURES OF CENTRAL TENDENCY [J].
DODGE, WF ;
JELLIFFE, RW ;
RICHARDSON, CJ ;
BELLANGER, RA ;
HOKANSON, JA ;
SNODGRASS, WR .
DRUG INVESTIGATION, 1993, 5 (04) :206-211
[7]
CLINICAL ASSESSMENT OF GESTATIONAL AGE IN NEWBORN INFANT [J].
DUBOWITZ, LM ;
DUBOWITZ, V ;
GOLDBERG, C .
JOURNAL OF PEDIATRICS, 1970, 77 (01) :1-+
[8]
Jelliffe R. W., 1994, Journal of Veterinary Pharmacology and Therapeutics, V17, P105
[9]
INDIVIDUALIZING DRUG-DOSAGE REGIMENS - ROLES OF POPULATION PHARMACOKINETIC AND DYNAMIC-MODELS, BAYESIAN FITTING, AND ADAPTIVE-CONTROL [J].
JELLIFFE, RW ;
SCHUMITZKY, A ;
VANGUILDER, M ;
LIU, M ;
HU, L ;
MAIRE, P ;
GOMIS, P ;
BARBAUT, X ;
TAHANI, B .
THERAPEUTIC DRUG MONITORING, 1993, 15 (05) :380-393
[10]
JELLIFFE RW, 1989, DM894 AM SOC CLIN PA